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Background: There has been no standard chemotherapy for 
advanced or recurrent thymic malignancies including thymic carci-
noma (TC) and invasive thymoma (IT), though platinum and anthra-
cycline have been reported as effective agents for the treatment of 
these diseases. The objective of this study was to evaluate the efficacy 
and safety of the combination of amrubicin (AMR), a new anthra-
cycline agent, and carboplatin (CBDCA) in patients with advanced 
thymic malignancies.
Methods: Patients with histologically confirmed thymic malignan-
cies received AMR (35 mg/m2, days 1–3) and CBDCA (area under the 
curve 4.0, day 1) every 3 weeks. Patients who had received previous 
chemotherapy were treated with a reduced dose of AMR (30 mg/m2). 
The primary end point was objective response rate (ORR), and sec-
ondary endpoints were progression-free survival, overall survival, 
and toxicity profile.
Results: From December 2008 to October 2012, 51 patients (33 TC 
and 18 IT) were enrolled. The median number of treatment cycles 
was four in each group. The ORR and progression-free survival were 
30% (95% confidence interval, 14–46) and 7.6 months in the TC 
group, and 17% (95% confidence interval, 0–34) and 7.6 months in 
the IT group, respectively. The ORR of TC patients without previous 
chemotherapy (n = 19) was 42%. Although grade 3 or 4 hemato-
logical toxicities were common including neutropenia (82%) and 
febrile neutropenia (22%), these were transient and manageable. 
Nonhematological toxicities were moderate and no treatment-related 
death was observed.
Conclusions: The combination of AMR with CBDCA was active 
for TC with acceptable toxicity, although it was not effective for IT. 
Further investigation of this regimen for advanced TC is warranted.
Key Words: Thymic carcinoma, Invasive thymoma, Chemotherapy, 
Amrubicin, Phase II.
(J Thorac Oncol. 2014;9: 1805–1809)
Thymic carcinoma (TC) is a rare thymic epithelial tumor, which tends to metastasize and invade the surrounding 
tissues rapidly. Thus, the prognosis of TC is quite poor in the 
metastatic stage (2-year survival rate is approximately 50%).1 
Although invasive thymoma (IT) has a relatively good progno-
sis compared with TC, it is also a fatal disease when accompa-
nied by distant metastasis. Patients with these advanced thymic 
malignancies are usually treated with systemic chemotherapy; 
however, due to the small number of patients with thymic malig-
nancies compared with those with lung cancer, there has been 
no evidence available from large comparative studies and no 
standard treatment for these conditions. According to the guide-
lines of the National Comprehensive Cancer Network, patients 
with advanced TC should be treated with a regimen similar to 
that used for patients with IT.2 Combined regimens consisting 
of platinum agent and anthracycline agents such as cisplatin, 
doxorubicin, and cyclophosphamide have been recommended 
for thymic malignancies,3 although these do not show adequate 
efficacy and the severe toxicities (e.g., emesis or renal toxicity 
with cisplatin, and cardiac toxicity with anthracycline) some-
times produce a decline in the patient’s quality of life.
Amrubicin (AMR) is a new anthracycline, which has 
achieved some promising results for advanced small-cell 
lung cancer in Japanese studies, as a single agent at a dose of 
45mg/m2 for three consecutive days, and also as a combined 
regimen with carboplatin (CBDCA, at a dose of area under 
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the curve 4), at a dose of 35mg/m2 on day 1 to 3.4–6 Although 
care should be taken with regard to myelosuppression dur-
ing the treatment with AMR, there have been few reports of 
cardiac toxicity induced by AMR to date. We postulated that 
the combination of AMR and CBDCA might show efficacy in 
treatment of advanced thymic malignancies with acceptable 
toxicities, and therefore conducted this phase II study.
PATIENTS AND METHODS
Patient Selection
This multicenter phase II trial was conducted in accor-
dance with the Helsinki Declaration of the World Medical 
Association and the protocol was approved by the institutional 
review board of each participating institution. Patients older 
than 20 years with histologically confirmed TC or IT were 
enrolled in this study. Other eligibility criteria included Eastern 
Cooperative Oncology Group performance status 0 to 1, mea-
surable lesion according to the Response Evaluation Criteria 
in Solid Tumors (RECIST) criteria, estimated life expectancy 
greater than or equal to 3 months, and appropriate organ func-
tions as follows: white blood cell count greater than or equal 
to 4000/mm3, absolute neutrophil count greater than or equal 
to 2000/mm3, platelets greater than or equal to 100,000/mm3, 
hemoglobin greater than or equal to 9.0 g/dl, serum bilirubin 
less than or equal to 1.5 mg/dl, aspartate aminotransferase and 
alanine aminotransferase less than or equal to 100 IU/L, cre-
atinine level less than or equal to 1.5 mg/dl, arterial oxygen 
pressure greater than or equal to 60 mmHg). Written informed 
consent was obtained from all the enrolled patients. Patients 
with symptomatic brain metastasis, interstitial lung disease, 
massive effusion requiring drainage, or severe comorbidities 
such as uncontrolled diabetes or cardiac disease were excluded. 
Patients who had received previous chemotherapy with doxo-
rubicin within 400 mg/m2 in total were included.
Treatment Schedule
AMR was diluted in 50ml of normal saline and adminis-
tered by 10-minute intravenous infusion at a dose of 35 mg/m2 
on days 1 to 3 of each treatment cycle. Patients who had 
received previous chemotherapy were treated with a reduced 
dose of AMR (30 mg/m2) to reduce the risk of myelotoxic-
ity. CBDCA was diluted in 250 ml of 5% glucose solution or 
normal saline and administered by ≥30-minute intravenous 
infusion at a dose of area under the curve 4.0 on day 1 after 
AMR. Doses of both the agents were determined according to 
our previous phase II study of this combination for untreated 
small-cell lung cancer patients.6 The treatment was repeated 
on a 21-day cycle. Premedication with corticosteroid and anti-
emetic serotonin antagonist was recommended. The dose of 
AMR was reduced by 5 mg/m2 in each subsequent cycle in 
case of severe toxic effects such as grade 3 or more nonhe-
matological toxicities, thrombocytopenia less than or equal 
to 20,000/mm3, grade 4 neutropenia lasting greater than or 
equal to 4 days, or febrile neutropenia occurring in the pre-
vious cycle. Granulocyte colony-stimulating factor (G-CSF) 
was permitted for neutropenia but not for use as a prophy-
lactic. No prophylactic antibiotic support was scheduled. All 
the patients were scheduled to receive at least three cycles of 
treatment unless their disease progressed, unacceptable tox-
icity occurred, the patient refused further treatment, or the 
physician decided to discontinue the treatment. Subsequent 
chemotherapy after disease progression was permitted.
Patient Assessment
Patient assessment, including physical examination, 
complete blood count, and biochemistry, were repeated once 
a week in the first cycle and at least once per each cycle later. 
Measurement of tumors was carried out with respect to base-
line assessment by computed tomography scans. Computed 
tomography examination was performed at least once per two 
cycles until disease progression. Tumor response was assessed 
according to RECIST version 1.1. Confirmation of complete 
and partial responses required at least 4 weeks duration of such 
responses, and stable disease required at least 4 weeks dura-
tion from the initiation of the protocol treatment. All response 
evaluations were performed by independent extramural review. 
Toxic effects were assessed according to the National Cancer 
Institute-Common Toxicity Criteria version 4.0.
Statistical Analysis
The primary end point of this study was objective 
response rate (ORR), and secondary endpoints included 
progression-free survival (PFS), overall survival, and toxic-
ity profile. Overall survival was evaluated for a period from 
the introduction of protocol treatment to the date of death. 
Assuming that ORR of 45% and 75% would indicate potential 
usefulness whereas ORR of 20% and 50% would be at the 
lower limit of interest, with alpha = 0.10 and beta = 0.20, for 
TC and IT, respectively, the estimated accrual was 18 for each 
group. Survival estimation was performed using the Kaplan-
Meier method. Differences between Kaplan-Meier curves 
were evaluated by log rank test.
RESULTS
Patient Characteristics
From December 2008 to October 2012, 51 patients (33 
TC and 18 IT) were enrolled from 18 institutions in Japan. 
Because the patient accrual was relatively slow in the IT 
group, accrual of the TC group was also expanded accom-
panied with the IT group. Patient characteristics are shown 
in Table 1. Twelve patients had previously received platinum-
based regimen such as CBDCA plus paclitaxel (nine patients) 
or cisplatin plus etoposide (four patients), and seven patients 
had been treated with doxorubicin mostly as doxorubicin, 
cisplatin, vincristine, and cyclophosphamide regimen before 
entering this study. Twenty-six (51%) patients received sub-
sequent chemotherapy including CBDCA plus paclitaxel (12 
patients) or S-1 (nine patients) after the protocol treatment.
Efficacy
The median number of treatment cycles was four in 
each group (range, 1–6 in TC, 2–15 in IT). Responses in all 
the 51 patients were evaluated. The ORR and disease control 
rates were 30% (95% confidence interval, 14–46) and 85% in 
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the TC group, and 17% (95% CI, 0–34), and 89% in the IT 
group, respectively (Table 2). The ORR of TC patients without 
previous chemotherapy (n = 19) was 42%.
At the data cutoff point in December 2013 when the 
median follow-up time of all the patients was 24 months, the 
median PFS and median survival time (MST) were 7.6 months 
and 27.3 months in the TC group and in the IT group were 7.6 
months and 58.0 months, respectively (Fig. 1). The efficacy 
stratified by various clinical factors is listed in Table 3, and 
shows a significant difference in OS between those aged less 
than or equal to 65 and greater than 65 years (p = 0.0208).
Safety
Toxicities (greater than or equal to grade 2) are summa-
rized in Table 4. Common toxicities greater than or equal to 
grade 3 were neutropenia (82%) including febrile neutropenia 
(22%), decreased hemoglobin (33%), and thrombocytopenia 
(20%). Twenty-eight (55%) patients required support with 
G-CSF for a median of 6 days (range, 2–11). Twelve (36%) 
patients in TC group and six (33%) patients in the IT group 
required dose reductions. Nonhematological toxicities were 
generally moderate. No cardiac toxicity was reported even in 
patients who had been previously treated with doxorubicin. 
No treatment-related deaths were observed.
DISCUSSIONS
The optimal chemotherapy for advanced thymic malig-
nancies remains unclear although platinum- and anthracy-
cline-containing triplet or quartet regimens such as cisplatin, 
doxorubicin, and cyclophosphamide or doxorubicin, cisplatin, 
vincristine, and cyclophosphamide have been used convention-
ally.7,8 The efficacy of high-dose chemotherapy such as cisplatin, 
vincristine, doxorubicin, and etoposide has also been reported.9 
However, it is generally toxic and requires long-term G-CSF 
support due to the severe myelotoxicity, which seems to be unfa-
vorable in general practice. Thus, an active regimen with accept-
able toxicity for patients with advanced thymic malignancies is 
eagerly anticipated. Recently, a combination of CBDCA and 
paclitaxel was reported which achieved a moderate response. 
The ORRs of this regimen were 21.7% (90% CI, 9.0–40.4) for 
TC (n = 23) and 42.9% (90% CI, 24.5–62.8) for IT (n = 21), 
respectively, which is now recommended for TC in the National 
Comprehensive Cancer Network guidelines.2,10 However, the 
associated severe peripheral neuropathy that reduces patient 
quality of life is a serious disadvantage of this regimen.11
This study revealed moderate efficacy of AMR and 
CBDCA in patients with advanced TC. In particular, the effi-
cacy in TC patients without previous chemotherapy (ORR, 
42%; 95% CI, 20–62) seems to be promising although it was 
from a subgroup analysis. The median PFS (7.6 months) and 
MST (27.3 months) in the TC group are also attractive com-
pared with previous results with other regimens including 
CBDCA plus paclitaxel (PFS, 5.0 months; MST, 20.0 months) 
for advanced TC.3,7,9,10,12,13 Thus, we believe further investiga-
tion of this regimen for TC patients is warranted. However, 
the efficacy of this regimen in IT patients is very disappoint-
ing. The reason for the low response rate in the IT group in 
this study remains unclear. It is possible that the evaluation by 
TABLE 1.  Patient Characteristics
Thymic Carcinoma Invasive Thymoma
(n = 33) (n = 18)
Gender
  Male/female 24/9 11/7
Age, median (range) 68 (39–78) 64 (44–76)
Performance status
  0/1 14/19 10/8
WHO classification
  A/B1/B2/B3 — 2/3/7/6
  C 33 —
Prior chemotherapy
  Yes (1 regimen/2 regimens) 7/7 2/1
   Regimen with doxorubicin 5 2
  No 19 15
Prior surgerya
  Yes/no 10/23 9/9
Prior radiationb
  Yes/no 6/27 5/13
aIncluding preoperative radiation.
bIncluding postoperative radiation.
WHO, World Health Organization.
TABLE 2.  Response
Thymic Carcinoma Invasive Thymoma
Prior Chemotherapy − + Total − + Total
n 19 14 33 15 3 18
Complete response 0 0 0 0 0 0
Partial response 8 2 10 2 1 3
Stable disease 8 10 18 11 2 13
Progressive disease 3 2 5 1 0 1
Not evaluable 0 0 0 1 0 1
  Overall response rate (%) (95% CI) 42 14 30 (14–46) 13 33 17 (0–34)
  Disease control rate (%) (95% CI) 84 86 85 (73–97) 87 100 89 (75–100)
CI, confidence interval.
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RECIST might be unsuitable for some cases, depending on 
the shape of their tumor.14 However, the PFS for IT patients in 
this study was also less than that of the previous studies for IT, 
so we conclude that this regimen is not active in IT. Because 
TC and IT are differently categorized, not only in terms of 
histology, but also with regard to clinical features and genetic 
backgrounds,15 it is unsurprising that the efficacies of some 
agents differ in the two disease states.
Regarding the toxicity profile, the current combination 
of AMR and CBDCA is quite acceptable. Although the inci-
dence of febrile neutropenia was relatively high, most events 
were observed during a short period and did not lead to severe 
A B
FIGURE 1. A, Kaplan–Meier curves for PFS and (B) OS of patients in TC group (blue line) and IT group (red line). Tick marks 
indicate patients for whom data were censored at the data cutoff point (December 2013). OS, overall survival; PFS, progression-
free survival; TC, thymic carcinoma; IT, invasive thymoma.
TABLE 3.  Efficacy Stratified by Various Clinical Factors
n ORR (%) DCR (%) MST (days) 1-Year OS (%) MPFS (days) 1-Year PFS (%)
Age (years)a ≤65 25 8 (32%) 23 (92%) 1763 92 344 37
>65 26 5 (19%) 21 (81%) 667 81 200 28
PS 0 24 7 (29%) 22 (92%) NR 96 231 31
1 27 6 (22%) 22 (81%) 1763 78 231 34
Gender Male 35 11 (31%) 29 (83%) NR 80 206 30
Female 16 2 (13%) 15 (94%) 1763 100 231 38
Histology A 2 0 2 (100%) NR 100 771 100
B1 3 0 2 (67%) NR 67 168 NR
B2 7 1 (14%) 7 (100%) NR 100 171 43
B3 6 2 (33%) 5 (83%) 1763 100 231 20
C 33 10 (30%) 28 (85%) 831 82 231 28
Prior chemo Yes 17 3 (18%) 15 (88%) 831 82 238 31
No 34 10 (29%) 29 (85%) NR 88 206 33
Prior DOX 
regimen
Yes 7 2 (29%) 6 (86%) 425 71 158 17
No 44 11 (25%) 38 (86%) 1763 89 238 34
No. of prior 
chemo 
regimens
0 34 10 (29%) 29 (85%) NR 88 206 33
1 9 1 (11%) 7 (78%) 831 67 200 13
2 8 2 (25%) 8 (100%) 1763 100 238 50
Prior surgery Yes 19 6 (32%) 17 (89%) 1763 95 267 39
No 32 7 (22%) 27 (84%) 831 81 213 28
Prior RT Yes 11 3 (27%) 10 (91%) 831 91 200 27
No 40 10(25%) 34 (85%) 1763 85 238 34
aA significant difference in OS between those aged ≤65 years and > 65 years (p = 0.0208, log rank test).
chemo, chemotherapy; DCR, disease control rate; DOX, doxorubicin; MPFS; median progression-free survival; MST; median survival time; NR, not reached; ORR, objective 
response rate; OS, overall survival; PS, performance status; RT, radiation.
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infectious disease. Rather, the low incidence of severe nonhema-
tological toxicities preserved the general condition of patients 
so that most received sufficient cycles of the treatment. Similar 
favorable toxicity profiles were observed in our previous stud-
ies,5,6,16 which could add support to the use of this regimen.
This study has some limitations. First, the sample size 
was too small to draw the definite conclusions. However, it is 
difficult to conduct a large comparative study of thymic tumor 
due to its rare incidence, and to the best of our knowledge, 
this is the largest prospective study of chemotherapy for thy-
mic malignancies. Second, the dosage of CBDCA may have 
been insufficient. Although we think that the current dosage 
was appropriate considering the current incidence of febrile 
neutropenia, there may be room to re-evaluate the balance of 
dosage of AMR and CBDCA.
In conclusion, although AMR combined with CBDCA 
was not effective in patients with IT, it was moderately active 
in TC with acceptable toxicities. Thus further investigation of 
this regimen for advanced TC is warranted.
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TABLE 4.  Toxicity
Number of Patients
Grade (CTCAE) 2 3 4 Grade 3/4
Hematological
  Neutropenia 4 14 28 42 (82%)
   Febrile neutropenia — 9 2 11 (22%)
  Anemia 15 16 1 17 (33%)
  Thrombocytopenia 12 8 2 10 (20%)
Nonhematological
  Nausea 7 2 0 2 (4%)
  Diarrhea 2 2 0 2 (4%)
  Infection 2 2 0 2 (4%)
  AST/ALT increased 1 1 0 1 (2%)
  Bilirubin increased 2 0 0 0
  Vomiting 1 0 0 0
  Fever 1 0 0 0
  Fatigue 1 0 0 0
  Mucositis oral 1 0 0 0
  Peripheral edema 1 0 0 0
  Constipation 1 0 0 0
  Hyperkalemia 1 0 0 0
ALT, alanine aminotransferase; AST, aspartate transaminase; CTCAE, common 
terminology criteria for adverse events.
